Klein H G, Santamarina-Fojo S, Duverger N, Clerc M, Dumon M F, Albers J J, Marcovina S, Brewer H B
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
J Clin Invest. 1993 Jul;92(1):479-85. doi: 10.1172/JCI116591.
We have identified the molecular defect in two siblings presenting with classical clinical and biochemical features of Fish Eye disease (FED), including corneal opacities, HDL cholesterol < 10 mg/dl, normal plasma cholesteryl esters, and elevated triglycerides. In contrast to previously reported patients with FED who are unable to esterify HDL-associated cholesterol, our patients' plasma lecithin-cholesterol acetyltransferase (alpha-LCAT)-specific activities assayed using an HDL-like proteoliposome substrate were 12.7-25.7 nmol/micrograms (19.5 +/- 1.8 in controls). In addition, significant residual cholesterol esterification was present in VLDL/LDL-depleted plasma, confirming the presence of HDL-associated alpha-LCAT activity. DNA sequence analysis of the proband's LCAT gene identified deletion of the triplet coding for leu300, which resulted in the loss of a restriction site for MlnI. Digestion of PCR-amplified DNA using MlnI established that both siblings are homozygous for this defect. Expression of LCAT300-del. in human embryonic kidney-293 cells revealed normal mRNA and intracellular LCAT concentrations. However, reduced amounts of LCAT300-del., which had a normal specific alpha-LCAT activity, were present in the media. In summary, we report the first case of FED associated with a mutant enzyme that has a normal alpha-LCAT-specific activity. The functional significance of this LCAT gene defect has been established in an in vitro expression system, which demonstrates that very small amounts of this functional LCAT mutant enzyme accumulate in the media. Characterization of LCAT300-del. established that selective alpha-LCAT deficiency is not a prerequisite for the development of FED. On the basis of our combined results, we propose that the residual amounts of total plasma LCAT activity and not its distribution on lipoproteins primarily determines the heterogeneity in phenotypic expression observed in familial LCAT deficiency syndromes.
我们已确定两名患有鱼眼病(FED)典型临床和生化特征的同胞的分子缺陷,这些特征包括角膜混浊、高密度脂蛋白胆固醇(HDL-C)<10mg/dl、血浆胆固醇酯正常以及甘油三酯升高。与先前报道的无法酯化HDL相关胆固醇的FED患者不同,我们的患者使用类HDL蛋白脂质体底物测定的血浆卵磷脂胆固醇酰基转移酶(α-LCAT)特异性活性为12.7 - 25.7nmol/μg(对照组为19.5±1.8)。此外,在极低密度脂蛋白/低密度脂蛋白(VLDL/LDL)耗尽的血浆中存在显著的残余胆固醇酯化,证实存在HDL相关的α-LCAT活性。对先证者的LCAT基因进行DNA序列分析,发现编码leu300的三联体缺失,这导致了MlnI限制性位点的丢失。使用MlnI对PCR扩增的DNA进行消化,确定两名同胞均为该缺陷的纯合子。LCAT300-del在人胚肾-293细胞中的表达显示mRNA和细胞内LCAT浓度正常。然而,培养基中存在的具有正常特异性α-LCAT活性的LCAT300-del量减少。总之,我们报告了首例与具有正常α-LCAT特异性活性的突变酶相关的FED病例。这种LCAT基因缺陷的功能意义已在体外表达系统中得到证实,该系统表明极少量的这种功能性LCAT突变酶在培养基中积累。对LCAT300-del的表征确定选择性α-LCAT缺乏不是FED发生的先决条件。基于我们的综合结果,我们提出血浆总LCAT活性的残余量而非其在脂蛋白上的分布主要决定了家族性LCAT缺乏综合征中观察到的表型表达异质性。